Herantis Pharma to publish financial statements for the first half of 2026 on August 20, 2026 - invitation to webcast presentation

Herantis Pharma Plc – Press release 10 August, 2026 at 9:50 EEST

Herantis Pharma to publish financial statements for the first half of 2026 on August 20, 2026 – invitation to webcast presentation

Espoo, Finland, 10 August 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announced it will release its financial statements for the first half of 2026 on Thursday, August 20, 2026.

Herantis Pharma's CEO Antti Vuolanto, CFO Tone Kvåle, and CMO Juha Savola will host a webcast on Thursday, August 20, 2026, at 10:00 am EEST (09:00 am CEST). The session will provide an overview of the report, current operations, and an update on preparations for the Phase 2 proof-of-concept efficacy study of HER-096.

The presentation will be delivered in English, followed by a Q&A session. Viewers can submit questions at any time throughout the webcast.

To join us, please register via this link: https://herantis.videosync.fi/q2-2026/register

A recording of the webcast will be available on the Company’s website after the event has concluded.

For more information, please contact:

Herantis Pharma Plc

Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com

ICR Healthcare
Sarah Elton-Farr, Stephanie Cuthbert, Phillip Marriage
Tel: +44 20 3709 5700
Email: herantispharma@icrhealthcare.com

Certified Advisor:

UB Corporate Finance Ltd
Tel: +358 9 25 380 225
Email: ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2027 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients.

Herantis is listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com